【沃森生物:13价肺炎结合疫苗为全球销售额最高的疫苗品种 但目前全球的缺口依然很大】沃森生物(300142.SZ)9月11日在投资者互动平台表示,尊敬的投资者,您好!根据康泰生物披露的公告,康泰生物研发的13价肺炎结合疫苗已获得药品注册证书。根据13价肺炎结合疫苗的市场销售数据,13价肺炎结合疫苗为全球销售额最高的疫苗品种,但目前全球的缺口依然很大。截至目前,包括康泰生物在内,全球仅有3家企业获得13价肺炎结合疫苗注册证书。(每日经济新闻)
沃森生物:上半年净利润同比增419% 加快新冠疫苗的临床和产业化进度 _ 东方财富网
eastmoney.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eastmoney.com Daily Mail and Mail on Sunday newspapers.
沃森生物:四价流脑疫苗启动国际临床试验 _ 东方财富网
eastmoney.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eastmoney.com Daily Mail and Mail on Sunday newspapers.
沃森生物:签署13价肺炎球菌多糖结合疫苗海外销售协议 _ 东方财富网
eastmoney.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eastmoney.com Daily Mail and Mail on Sunday newspapers.
沃森生物拟卖资产背后:两度收购惠生系公司 _ 东方财富网
eastmoney.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eastmoney.com Daily Mail and Mail on Sunday newspapers.